Hasty Briefs - Daily Tech News Brief

Bilingual

Short-chain acyl-CoA dehydrogenase initiates mtDNA demethylation and leakage to fuel antitumor immunity in colorectal cancer - PubMed
a month ago
- ACADS deficiency in colorectal cancer cells promotes tumor progression by suppressing cGAS-STING signaling and creating an immunosuppressive tumor microenvironment.
- ACADS inhibits mito-DNMT1 to prevent mtDNA methylation, stabilizing mtDNA and reducing its leakage into the cytoplasm, which otherwise activates cGAS-STING.
- Modulating mito-DNMT1 can reverse the effects of ACADS deficiency, restoring antitumor immunity and inhibiting CRC growth.
- The drug hypericin was identified as an ACADS-binding compound that mimics ACADS overexpression, improving the immune TME and suppressing CRC.
Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer - PubMed
a month ago
- The article comments on the use of Sacituzumab Govitecan in untreated, advanced triple-negative breast cancer.
- A related clinical trial (N Engl J Med. 2025 Nov 13) discusses the drug's efficacy in this patient population.
- The referenced study was published online in October 2025, with specific details available via its PMID and DOI.
Soluble cytokines and chemokines in NSCLC: drivers of immune evasion and angiogenesis - PubMed
a month ago
- Soluble cytokines and chemokines in the tumor microenvironment drive immune evasion, angiogenesis, and metastasis in NSCLC.
- Key mediators include IL-6, IL-8, IL-10, CXCL12-CXCR4, CCL21-CCR7, VEGF, bFGF, and MMPs, which modulate immune cell recruitment, EMT, and vascular remodeling.
- Cytokine signatures in blood serve as prognostic biomarkers and predictors for immunotherapy efficacy, offering opportunities for biomarker-guided precision therapy in NSCLC.
Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies - PubMed
a month ago
- Immunotherapy combinations are the first-line standard of care for advanced HCC, replacing tyrosine kinase inhibitors (TKIs).
- Despite high response rates, only 20-30% of patients respond to first-line immunotherapy, with about 50% progressing at 6 months.
- TKIs are effective and safe for patients who progress on immunotherapy, as supported by recent studies.
- Novel strategies include adding a third immune checkpoint inhibitor or combining locoregional therapies like TACE with systemic treatments.
- Phase 3 trials (EMERALD-1, LEAP-012, TALENTACE) show survival benefits from combining TACE and immunotherapy over TACE alone.
- Combination therapies enable downstaging and conversion to curative options due to higher response rates.
- Cellular therapy shows promise in early studies, potentially expanding immunotherapy options beyond checkpoint inhibitors.
A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy - PubMed
a month ago
- Developed CLDN6 nanobody-based bispecific T-cell engager (BiTE) using self-amplifying mRNA and lipid nanoparticles for targeted ovarian cancer therapy.
- CLDN6-Nb-BiTE demonstrated robust in vitro cytotoxicity and cytokine release, and in vivo tumor control without systemic toxicity.
- This approach overcomes limitations of protein-based BiTEs, offering a promising immunotherapy for ovarian cancer with potential for durable treatment.
Engineering in vivo CAR-T cells - PubMed
a month ago
- Focus on engineering CAR-T cells within the living body (in vivo).
- No competing interests declared by the authors.
- Primary topic is CAR-T cell therapy advancements in vivo.
The cGAS-STING pathway in cancer: friend or foe - PubMed
a month ago
- The cGAS-STING pathway detects aberrant cytoplasmic DNA and activates innate immunity, producing type I interferons to trigger antitumor immune responses.
- Its role in cancer is dual, with both antitumor and pro-tumor effects, making it a complex target for immunotherapy.
- This review explores how cGAS avoids self-DNA recognition, details its mechanisms in cancer progression and suppression, and discusses therapeutic strategies.
SYT8 Drives Colorectal Cancer Progression and Immune Evasion via the SETD1A-H3K4me3 Axis - PubMed
a month ago
- SYT8 is significantly upregulated in colorectal cancer tumors and predicts poor prognosis.
- SYT8 expression is primarily in tumor cell nuclei and promotes cancer cell proliferation and invasion.
- SYT8 depletion reduces while overexpression enhances CRC progression and epithelial-mesenchymal transition (EMT).
- SYT8 interacts directly with SETD1A, forming a positive-feedback loop that increases H3K4me3 levels.
- The SYT8-SETD1A axis activates pro-tumorigenic genes, driving cell cycle and EMT.
- High SYT8 expression correlates with increased regulatory T-cell infiltration, suggesting immune evasion and potential immunotherapy resistance.
- SYT8 promotes CRC progression via SETD1A/H3K4me3-mediated activation, EMT induction, and immune microenvironment remodeling.
- SYT8 is established as a prognostic biomarker and therapeutic target in colorectal cancer.

Hasty Briefsbeta

#immunotherapy

Short-chain acyl-CoA dehydrogenase initiates mtDNA demethylation and leakage to fuel antitumor immunity in colorectal cancer - PubMed

Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer - PubMed

Soluble cytokines and chemokines in NSCLC: drivers of immune evasion and angiogenesis - PubMed

Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies - PubMed

A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy - PubMed

Engineering in vivo CAR-T cells - PubMed

The cGAS-STING pathway in cancer: friend or foe - PubMed

SYT8 Drives Colorectal Cancer Progression and Immune Evasion via the SETD1A-H3K4me3 Axis - PubMed